Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS
- 1 November 2017
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 18 (11) , e638
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Oncology, 2017
- Targeting PI3K/AKT pathway in triple-negative breast cancerThe Lancet Oncology, 2017
- Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitorsAnnals of Oncology, 2017
- Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordanceAnnals of Oncology, 2017
- Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in OncologyJAMA Oncology, 2017